A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant-Reference-Cited by-同舟云学术

A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant

Published:2022-07 Issue:4 Volume:21 Page:675-683
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Sawicki Gregory S.,Chilvers Mark,McNamara John,Naehrlich Lutz^ORCID,Saunders Clare^ORCID,Sermet-Gaudelus Isabelle,Wainwright Claire E.,Ahluwalia Neil^ORCID,Campbell Daniel,Harris R. Scott,Paz-Diaz Hildegarde,Shih Judy L.,Davies Jane C.

Funder

Vertex Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference34 articles.

1. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening;Stick;J Pediatr,2009

2. Structural airway abnormalities in infants and young children with cystic fibrosis;Long;J Pediatr,2004

3. High-resolution computed tomography imaging of airway disease in infants with cystic fibrosis;Martínez;Am J Respir Crit Care Med,2005

4. Progression of lung disease in preschool patients with cystic fibrosis;Stanojevic;Am J Respir Crit Care Med,2017

5. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis;Gustafsson;Thorax,2008

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis;The Lancet;2023-09

2. Cystic fibrosis year in review 2022;Pediatric Pulmonology;2023-08-18

3. Nutritional management of people living with cystic fibrosis throughout life and disease continuum: Changing times, new challenges;Journal of Human Nutrition and Dietetics;2023-07-28

4. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis – a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI;Journal of Cystic Fibrosis;2023-07

5. Cystic fibrosis and other ion channel-related diseases;Rare Diseases of the Respiratory System;2023-06-01